Acumen Pharmaceuticals, Inc. Payments to Acquire Marketable Securities
Acumen Pharmaceuticals, Inc. (ABOS) reported Payments to Acquire Marketable Securities of $40.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $40.82M, a 16.48% increase year-over-year.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for fiscal 2025 was $38.06M, a 77.71% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for fiscal 2024 was $170.73M, a 31.88% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for fiscal 2023 was $250.63M, a 503.73% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. payments to acquire marketable securities for fiscal 2022 was $41.51M, a 60.11% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $40.82M 10-Q · filed 2026-08-12 | $40.82M derived: sum of 3 quarters · filed 2026-08-12 | $40.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $40.82M 10-Q · filed 2026-05-12 | $40.82M derived: sum of 2 quarters · filed 2026-05-12 | $40.82M derived: sum of 3 quarters · filed 2026-05-12 | $43.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $3.01M derived: sum of 3 quarters · filed 2026-08-12 | $38.06M 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.01M derived: sum of 2 quarters · filed 2026-08-12 | $38.06M 10-Q · filed 2025-11-12 | $53.16M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $38.06M 10-Q · filed 2026-08-12 | $53.16M derived: sum of 3 quarters · filed 2026-08-12 | $151.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $35.05M 10-Q · filed 2026-05-12 | $50.15M derived: sum of 2 quarters · filed 2026-05-12 | $148.69M derived: sum of 3 quarters · filed 2026-05-12 | $160.49M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $15.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $113.64M derived: sum of 2 quarters · filed 2026-03-26 | $125.44M derived: sum of 3 quarters · filed 2026-03-26 | $170.73M 10-K · filed 2026-03-26 |
| 2024-09-30 | $98.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $110.34M derived: sum of 2 quarters · filed 2025-11-12 | $155.63M 10-Q · filed 2025-11-12 | $227.41M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $11.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $57.09M 10-Q · filed 2025-08-12 | $128.87M derived: sum of 3 quarters · filed 2025-08-12 | $255.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $45.29M 10-Q · filed 2025-05-13 | $117.07M derived: sum of 2 quarters · filed 2025-05-13 | $243.79M derived: sum of 3 quarters · filed 2025-05-13 | $243.79M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $71.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $198.50M derived: sum of 2 quarters · filed 2025-03-27 | $198.50M derived: sum of 3 quarters · filed 2025-03-27 | $250.63M 10-K · filed 2025-03-27 |
| 2023-09-30 | $126.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $126.73M derived: sum of 2 quarters · filed 2024-11-12 | $178.86M 10-Q · filed 2024-11-12 | $208.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $52.13M 10-Q · filed 2024-08-13 | $81.52M derived: sum of 3 quarters · filed 2024-08-13 | $81.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $52.13M 10-Q · filed 2024-05-14 | $81.52M derived: sum of 2 quarters · filed 2024-05-14 | $81.52M derived: sum of 3 quarters · filed 2024-05-14 | $84.56M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $29.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $29.39M derived: sum of 2 quarters · filed 2024-03-26 | $32.42M derived: sum of 3 quarters · filed 2024-03-26 | $41.51M 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.04M derived: sum of 2 quarters · filed 2023-11-13 | $12.13M 10-Q · filed 2023-11-13 | $22.11M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $12.13M 10-Q · filed 2023-08-08 | $22.11M derived: sum of 3 quarters · filed 2023-08-08 | |
| 2022-03-31 | $9.09M 10-Q · filed 2023-05-09 | $19.07M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $9.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $104.08M 10-K · filed 2023-03-27 | ||
| 2021-09-30 | $94.09M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |